CBAY CymaBay Therapeutics Inc.

CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

NEWARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, August 10, 2020 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter and six months ended June 30, 2020 and to provide a business update.

Conference Call Details

To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13706143. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at . 

About CymaBay

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.  CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA and PRIority MEdicines status from the EMA for PBC.

For additional information about CymaBay visit .

Public Relations Contact:            

Glenn Silver

Lazar-FINN Partners

(973) 818-8198

 

Investor Relations Contact:

Hans Vitzthum

LifeSci Advisors, LLC

(617) 430-7578

EN
03/08/2020

Underlying

CBAYCymaBay Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CymaBay Therapeutics Inc.

 PRESS RELEASE
Free
CBAY CymaBay Therape...

CymaBay Announces European Medicines Agency Accepts for Review the Mar...

CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis MAA Validation Follows Recent Applications for Seladelpar to the U.K. MHRA and U.S. FDA NEWARK, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the Marketing Authorization Application (MAA) for seladelpar, for the treatment of primary biliary cholangitis ...

March 4, 2024 1 EN
 PRESS RELEASE
Free
CBAY CymaBay Therape...

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financ...

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.  U.S. FDA accepted seladelpar NDA for priority review, and seladelpar marketing applications were submitted to the EMA and MHRA for review in Europe and the U.K. Due to the pending transaction with Gilead, CymaBay will not be hosting a conference call to review the financial results for the fourth quarter ended December 31, 2023 or commenting on it...

February 28, 2024 1 EN
 PRESS RELEASE
Free
CBAY CymaBay Therape...

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(...

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEWARK, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to three employees on February 16, 2024 (the “Grant Date”) in connection with the employees’ commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymBay approved the grant of non-qualified stock options to ...

February 20, 2024 1 EN
 PRESS RELEASE
Free
CBAY CymaBay Therape...

CymaBay Therapeutics to Participate in Upcoming Investment Conferences

CymaBay Therapeutics to Participate in Upcoming Investment Conferences NEWARK, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, February 7-8, in New York, NY, Raymond James & Associates’ 45th Annual Institutional Investors Conference, March 4-6, in Orlando, Florida, and Leerink Partners Global Biopharma C...

January 31, 2024 1 EN
 PRESS RELEASE
Free
CBAY CymaBay Therape...

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(...

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEWARK, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to two employees on January 12, 2024 (the “Grant Date”) in connection with the employees’ commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymBay approved the grant of non-qualified stock options to pur...

January 16, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch